Investment
Features
FeesSafety
Academy
More
Pluang+

Aave lets automated agents manage Pendle collateral risk on Plasma with strict update limits.

Protocol Fundamentals
05 Oct 2026
Crypto Briefing
View Source
Bullish
Aave lets automated agents manage Pendle collateral risk on Plasma with strict update limits.

Aave has proposed a governance plan to allow LlamaRisk's automated LlamaGuard agents to manage risk parameters for the Pendle Principal Token PT-sUSDe-22OCT2026 on the Plasma network. These agents, running on Chainlink's Runtime Environment, will adjust collateral settings like interest rates and liquidation thresholds within strict limits, including capped changes and minimum cooldown periods. This move follows a successful Ethereum deployment and signals Aave's confidence in automated risk management across multiple networks, potentially expanding this model to other assets and chains. Borrowers can expect more frequent but smaller parameter adjustments, reducing sudden shocks to their positions.

The story about Aave's governance plan for LlamaRisk agents managing Pendle collateral is presented here with Pluang's market data for context. For readers following major cryptocurrencies, 25 rose and 24 fell out of 50 priced assets today. Notable moves include SXP down 46.27%, BAL up 11.14%, and SAND down 10.29%, as of Oct 06, 2026 01:32 WIB.

More News

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital eyes $1B net income by 2027 amid AI data center expansion, Q1 loss expected.

Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...

Company Fundamentals
Bullish
1 hour ago
Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Needham raises Vaxcyte price target after strong Phase 3 trial of VAX-31 vaccine

Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...

Analyst Insights
Bullish
2 hours ago
GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's Rina-S shows 45.9% response in ovarian cancer trial, advancing to Phase 3 studies.

GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...

Market News
Bullish
3 hours ago
Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

Class action lawsuit filed against Alphabet over misleading statements on Gemini 3.5 Pro delays

A class action lawsuit has been filed against Alphabet Inc. for allegedly making false and misleading statements about the performance and launch delays of its Gemini 3.5 Pro product between May 19 and July 16, 2026. The lawsuit claims these misstate...

Market News
Bearish
4 hours ago
McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's shares drop over 30%, a rare plunge linked to rising US Treasury yields.

McDonald's stock has fallen more than 30%, a rare event seen only a few times in 40 years, mainly due to rising US 10-year Treasury yields making safer investments more attractive compared to McDonald's dividend. Despite the price drop, McDonald's fu...

Market News
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App